Reston,
VA (August 11, 2025)--The
Society of Nuclear Medicine and Molecular Imaging (SNMMI) is proud to announce the
launch of the Global Radiopharmaceutical Trial Finder a revolutionary,
AI-powered platform designed to help researchers, clinicians and patients
instantly discover radiopharmaceutical clinical trials that meet their specific
needs. This initiative represents a concrete step toward SNMMI s goal of
ensuring patient access to life-changing nuclear medicine procedures.
Developed
by Ancora.ai and hosted on the SNMMI website, the Trial Finder is designed to
eliminate barriers to clinical trial participation by offering a streamlined,
user-friendly experience for physicians, patients, and researchers. The platform
utilizes real-time global trials data refreshed every 24 hours from ClinicalTrials.gov
and three additional international registries. No personal information is
stored or sold.
Clinical
trials are essential to the development of new radiopharmaceuticals, which have
the potential to diagnose, treat, and in some cases cure cancer and other
diseases. According to data from the National Institutes
of Health, 84% of
patients would consider participating in a clinical trial if suggested by their
physician, but only 3% to 5% of eligible adult cancer patients actually enroll.
The Trial Finder aims to help close that gap.
Patients begin by selecting their condition
and ZIP code. The Trial Finder then guides them through specific questions
about disease stage, prior treatment, and other key factors, returning a tailored
list of trials for which they may be eligible. Each result includes the strength
of the match to
the trial criteria and the trial site s distance from their location.
Physicians use the same interface to match
patients with relevant trials, helping identify appropriate opportunities
quickly and accurately.
Researchers can search thousands of radiopharmaceutical
trials worldwide using specific parameters such as trial phase, type of
radionuclide, and target. The real-time Quick Charts feature provides a
detailed breakdown of trial types, locations, sponsors and other criteria.
The
Global Radiopharmaceutical Trial Finder is a powerful example of how AI can be
harnessed to make nuclear medicine more accessible to patients. With this tool,
patients and their referring providers have life-saving care at their
fingertips.
The
Global Radiopharmaceutical Trial Finder is available at www.snmmi.org/TrialFinder.
###
About the Society of Nuclear Medicine and Molecular Imaging
The
Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international
scientific and medical organization dedicated to advancing nuclear medicine,
molecular imaging, and theranostics precision medicine that allows diagnosis
and treatment to be tailored to individual patients in order to achieve the
best possible outcomes. For more information, visit snmmi.org.
About AncoraAI
AncoraAi uses technology
and a patient-first approach to democratize clinical trial access, so that
every patient has the best chances of recovery and leading a healthy life.